PRPS1 and achondroplasia: Our disease candidates for gain-of-function mutations in Table 1 include known over-activation diseases with inhibitor drug developments on trial, like PRPS1 superactivity (MIM: 300661) and achondroplasia (MIM: 100800) [20, 21].